BEVERLY, MA–(Marketwired – August 03, 2015) - Cellceutix Corporation (OTC: CTIX) (the “Company”), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce the selection and addition of two clinical sites to be joining the Company’s ongoing Phase 2 clinical trial of Brilacidin-OM for the treatment and prevention of oral mucositis in patients with head and neck cancer. Cellceutix expects recruitment to commence in the coming weeks at the centers, bringing the total number of clinical sites in the study to date to five.
Increasing patient access to the trial is important in the Company’s efforts to discover an effective, safe therapy for oral mucositis and also to prove the anti-inflammatory properties of Brilacidin in a clinical setting. Laboratory studies have shown Brilacidin to have antibacterial and anti-inflammatory properties. Two successfully completed Phase 2 clinical trials of Brilacidin for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) have demonstrated Brilacidin’s ability to rapidly destroy bacteria.
“We are already confident in Brilacidin’s anti-infective properties and believe it will be a true breakthrough if Brilacidin works as an anti-inflammatory as well,” commented Leo Ehrlich, Chief Executive Officer at Cellceutix. “This trial has many implications because, as large as the anti-infective market is, the anti-inflammatory market potential for Brilacidin is even greater. I think it is important for shareholders to understand this and the potential value it brings to the Company. As we collect and analyze data from this trial, it will provide direction in our goal to initiate trials addressing the anti-inflammatory markets. Overall, I am very pleased and excited by what I have seen to date in all of our clinical trials and look forward to providing shareholders with a more comprehensive update upon receipt of additional data from all the participating vendors and clinical sites.”